Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas

APMIS

Volumn 110, Issue 3, 2002, Pages 229-238

  Oh, Ro Ra ^a   Park, Jik Young ^a   Lee, Jong Heun ^a   Shin, Min Sun ^a   Kim, Hong Sug ^a   Lee, Sang Kyu ^a   Kim, Young Sil ^a   Lee, Sug Hyung ^a   Lee, Sie Nae ^a   Yang, Young Mok ^b   Yoo, Nam Jin ^a   Lee, Jung Young ^a   Park, Won Sang ^a  

^a The Catholic University of Korea   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

Immunohistochemistry; LOH; Methylation; Mutation

Indexed keywords

ADULT; AGED; ARTICLE; AUTOPHOSPHORYLATION; CANCER INVASION; CELL TYPE; FEMALE; GENE INACTIVATION; GENE LOCATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; TUMOR SUPPRESSOR GENE;

ADULT; AGED; CARCINOMA, RENAL CELL; CPG ISLANDS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LIGASES; LOSS OF HETEROZYGOSITY; MALE; METHYLATION; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-MET; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0036242160     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2002.100305.x     Document Type: Article

References (35)

1. Classification of renal cell carcinoma: Workgroup No. I
2. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinoma
3. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
4. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C
5. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein
6. Renal carcinoma
7. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
8. Regulation of mitogenesis, motogenesis, and tubulogenesis by hepatocyte growth factor in renal collecting duct cells
9. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor
10. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells
11. Expression of the Met/HGF receptor in normal and neoplastic human tissues
12. The mutationally activated Met receptor mediates motility and metastasis
13. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation
14. C-met proto-oncogene expression in benign and malignant human renal tissues
15. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion branching morphogenesis in renal carcinoma cells
16. Induction of tissue inhibitor metalloporteinases-3 is a delayed early cellular response to hepatocyte growth factor
17. Renal parenchymal neoplasms
18. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections
19. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas
20. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas
21. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
22. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas
23. Germline mutations in the von Hippel-Lindau disease gene (VHL) in families form North America, Europe, and Japan
24. Mutations of the VHL tumor suppressor gene in renal carcinoma
25. Mutations of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas
26. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinoma
27. Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein
28. Inhibition of transcription elongation by the VHL tumor suppressor protein
29. Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutations
30. Regulation of hypoxia-inducible mRNAs by the von-Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2
31. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors
32. The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions
33. Insight into the structure of hepatocyte growth factor/scatter factor (HGF/SF) and implications for receptor activation
34. Creation of a hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity
35. The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit